Medirom Historical Financial Ratios
MRM Stock | USD 0.93 0.01 1.06% |
Medirom Healthcare is lately reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 21.35 will help investors to properly organize and evaluate Medirom Healthcare financial condition quickly.
Medirom |
About Medirom Financial Ratios Analysis
Medirom HealthcareFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Medirom Healthcare investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Medirom financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Medirom Healthcare history.
Medirom Healthcare Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Medirom Healthcare stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Medirom Healthcare sales, a figure that is much harder to manipulate than other Medirom Healthcare Technologies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Medirom Healthcare Technologies dividend as a percentage of Medirom Healthcare stock price. Medirom Healthcare dividend yield is a measure of Medirom Healthcare stock productivity, which can be interpreted as interest rate earned on an Medirom Healthcare investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Most ratios from Medirom Healthcare's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Medirom Healthcare current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Medirom Healthcare's Days Of Inventory On Hand is very stable compared to the past year. As of the 24th of January 2025, Days Payables Outstanding is likely to grow to 16.50, while Book Value Per Share is likely to drop 41.43.
2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 24.34 | 38.19 | 34.37 | 21.99 | Days Of Inventory On Hand | 8.24 | 9.72 | 8.74 | 9.18 |
Medirom Healthcare fundamentals Correlations
Click cells to compare fundamentals
Medirom Healthcare Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Medirom Healthcare fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Ptb Ratio | 12.18 | (16.31) | (54.48) | 19.75 | 17.78 | 18.66 | |
Days Sales Outstanding | 16.22 | 21.07 | 28.06 | 33.24 | 29.92 | 21.35 | |
Book Value Per Share | 122.06 | (42.72) | (10.85) | 41.81 | 48.08 | 41.43 | |
Free Cash Flow Yield | (0.0735) | (0.19) | (0.25) | (0.18) | (0.21) | (0.22) | |
Operating Cash Flow Per Share | (91.05) | (114.25) | (125.34) | (122.29) | (140.64) | (147.67) | |
Capex To Depreciation | 1.18 | 0.76 | 0.66 | 0.54 | 0.62 | 0.75 | |
Pb Ratio | 12.18 | (16.31) | (54.48) | 19.75 | 17.78 | 18.66 | |
Ev To Sales | 1.93 | 0.94 | 0.73 | 1.13 | 1.3 | 1.77 | |
Free Cash Flow Per Share | (109.32) | (133.86) | (147.41) | (148.59) | (170.88) | (179.42) | |
Roic | (0.18) | (0.27) | 0.0202 | (0.48) | (0.55) | (0.52) | |
Inventory Turnover | 366.1 | 213.57 | 44.27 | 37.57 | 43.21 | 41.04 | |
Net Income Per Share | (133.97) | (203.13) | 27.23 | 22.27 | 20.04 | 21.05 | |
Days Of Inventory On Hand | 1.0 | 1.71 | 8.24 | 9.72 | 8.74 | 9.18 | |
Payables Turnover | 43.46 | 17.3 | 24.34 | 38.19 | 34.37 | 21.99 | |
Capex To Revenue | 0.022 | 0.0177 | 0.0174 | 0.0199 | 0.0179 | 0.0118 | |
Cash Per Share | 365.82 | 77.32 | 110.77 | 20.68 | 23.79 | 22.6 | |
Pocfratio | (16.33) | (6.1) | (4.72) | (6.59) | (7.58) | (7.2) | |
Interest Coverage | (48.33) | (33.09) | 9.89 | (10.62) | (12.21) | (12.82) | |
Capex To Operating Cash Flow | (0.2) | (0.17) | (0.18) | (0.22) | (0.25) | (0.23) | |
Pfcf Ratio | (13.6) | (5.2) | (4.01) | (5.43) | (6.24) | (5.93) | |
Days Payables Outstanding | 8.4 | 21.1 | 15.0 | 9.56 | 10.99 | 16.5 | |
Income Quality | 0.68 | 0.56 | (4.6) | (5.49) | (6.31) | (6.0) | |
Roe | (1.1) | 4.76 | (2.51) | 0.55 | 0.49 | 0.52 | |
Ev To Operating Cash Flow | (17.6) | (9.09) | (7.42) | (12.2) | (14.03) | (13.33) | |
Pe Ratio | (11.1) | (3.43) | 21.71 | 36.2 | 41.63 | 39.55 | |
Return On Tangible Assets | (0.0987) | (0.21) | 0.0257 | 0.0211 | 0.0243 | 0.0255 | |
Ev To Free Cash Flow | (14.65) | (7.76) | (6.31) | (10.04) | (11.55) | (10.97) | |
Earnings Yield | (0.0901) | (0.29) | 0.0461 | 0.0276 | 0.0249 | 0.0261 | |
Intangibles To Total Assets | 0.0435 | 0.17 | 0.14 | 0.21 | 0.18 | 0.19 | |
Net Debt To E B I T D A | (0.8) | (6.19) | 6.6 | 11.43 | 13.14 | 13.8 | |
Current Ratio | 0.79 | 0.43 | 0.65 | 0.49 | 0.44 | 0.45 | |
Tangible Book Value Per Share | 60.36 | (245.98) | (183.26) | (230.23) | (264.76) | (251.52) | |
Receivables Turnover | 22.5 | 17.32 | 13.01 | 10.98 | 12.63 | 16.05 | |
Graham Number | 606.58 | 441.85 | 81.55 | 143.02 | 128.72 | 196.66 | |
Shareholders Equity Per Share | 122.06 | (42.72) | (10.85) | 40.82 | 46.95 | 41.24 | |
Debt To Equity | 3.87 | (9.78) | (41.46) | 17.31 | 15.57 | 16.35 | |
Capex Per Share | 18.28 | 19.61 | 22.07 | 26.3 | 23.67 | 12.7 | |
Graham Net Net | (903.1) | (1.1K) | (1.0K) | (1.2K) | (1.3K) | (1.4K) | |
Revenue Per Share | 830.31 | 1.1K | 1.3K | 1.3K | 1.2K | 823.29 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.